Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Evaluation Study of Healthy Chinese Volunteers After Oral Administration of SHR1459 Tablets in Old and New Formulation

Trial Profile

Pharmacokinetic Evaluation Study of Healthy Chinese Volunteers After Oral Administration of SHR1459 Tablets in Old and New Formulation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edralbrutinib (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Membranous glomerulonephritis; Neuromyelitis optica; Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 04 Nov 2022 Status changed from not yet recruiting to completed.
  • 26 May 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top